272 related articles for article (PubMed ID: 21666061)
1. Unexpected role for granzyme K in CD56bright NK cell-mediated immunoregulation of multiple sclerosis.
Jiang W; Chai NR; Maric D; Bielekova B
J Immunol; 2011 Jul; 187(2):781-90. PubMed ID: 21666061
[TBL] [Abstract][Full Text] [Related]
2. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.
Bielekova B; Catalfamo M; Reichert-Scrivner S; Packer A; Cerna M; Waldmann TA; McFarland H; Henkart PA; Martin R
Proc Natl Acad Sci U S A; 2006 Apr; 103(15):5941-6. PubMed ID: 16585503
[TBL] [Abstract][Full Text] [Related]
3. An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells.
Martin JF; Perry JS; Jakhete NR; Wang X; Bielekova B
J Immunol; 2010 Jul; 185(2):1311-20. PubMed ID: 20543101
[TBL] [Abstract][Full Text] [Related]
4. Dysregulation of regulatory CD56(bright) NK cells/T cells interactions in multiple sclerosis.
Laroni A; Armentani E; Kerlero de Rosbo N; Ivaldi F; Marcenaro E; Sivori S; Gandhi R; Weiner HL; Moretta A; Mancardi GL; Uccelli A
J Autoimmun; 2016 Aug; 72():8-18. PubMed ID: 27157273
[TBL] [Abstract][Full Text] [Related]
5. Daclizumab Therapy for Multiple Sclerosis.
Bielekova B
Cold Spring Harb Perspect Med; 2019 May; 9(5):. PubMed ID: 29661806
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the Impact of Daclizumab Beta on Circulating Natural Killer Cells by Mass Cytometry.
Ranganath T; Simpson LJ; Ferreira AM; Seiler C; Vendrame E; Zhao N; Fontenot JD; Holmes S; Blish CA
Front Immunol; 2020; 11():714. PubMed ID: 32391016
[TBL] [Abstract][Full Text] [Related]
7. Cutting edge: in vivo blockade of human IL-2 receptor induces expansion of CD56(bright) regulatory NK cells in patients with active uveitis.
Li Z; Lim WK; Mahesh SP; Liu B; Nussenblatt RB
J Immunol; 2005 May; 174(9):5187-91. PubMed ID: 15843513
[TBL] [Abstract][Full Text] [Related]
8. Population PK-PD analyses of CD25 occupancy, CD56
Diao L; Hang Y; Othman AA; Mehta D; Amaravadi L; Nestorov I; Tran JQ
Br J Clin Pharmacol; 2016 Nov; 82(5):1333-1342. PubMed ID: 27333593
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis.
Perry JS; Han S; Xu Q; Herman ML; Kennedy LB; Csako G; Bielekova B
Sci Transl Med; 2012 Aug; 4(145):145ra106. PubMed ID: 22855463
[TBL] [Abstract][Full Text] [Related]
10. Daclizumab therapy for multiple sclerosis.
Bielekova B
Neurotherapeutics; 2013 Jan; 10(1):55-67. PubMed ID: 23055048
[TBL] [Abstract][Full Text] [Related]
11. Intermediate-affinity interleukin-2 receptor expression predicts CD56(bright) natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis.
Sheridan JP; Zhang Y; Riester K; Tang MT; Efros L; Shi J; Harris J; Vexler V; Elkins JS
Mult Scler; 2011 Dec; 17(12):1441-8. PubMed ID: 21807759
[TBL] [Abstract][Full Text] [Related]
12. Daclizumab reduces CD25 levels on T cells through monocyte-mediated trogocytosis.
Zhang Y; McClellan M; Efros L; Shi D; Bielekova B; Tang MT; Vexler V; Sheridan JP
Mult Scler; 2014 Feb; 20(2):156-64. PubMed ID: 23846354
[TBL] [Abstract][Full Text] [Related]
13. CD56bright human NK cells differentiate into CD56dim cells: role of contact with peripheral fibroblasts.
Chan A; Hong DL; Atzberger A; Kollnberger S; Filer AD; Buckley CD; McMichael A; Enver T; Bowness P
J Immunol; 2007 Jul; 179(1):89-94. PubMed ID: 17579025
[TBL] [Abstract][Full Text] [Related]
14. Systematic characterization of human CD8+ T cells with natural killer cell markers in comparison with natural killer cells and normal CD8+ T cells.
Ohkawa T; Seki S; Dobashi H; Koike Y; Habu Y; Ami K; Hiraide H; Sekine I
Immunology; 2001 Jul; 103(3):281-90. PubMed ID: 11454057
[TBL] [Abstract][Full Text] [Related]
15. Human CD56bright and CD56dim natural killer cell subsets respond differentially to direct stimulation with Mycobacterium bovis bacillus Calmette-Guérin.
Batoni G; Esin S; Favilli F; Pardini M; Bottai D; Maisetta G; Florio W; Campa M
Scand J Immunol; 2005 Dec; 62(6):498-506. PubMed ID: 16316416
[TBL] [Abstract][Full Text] [Related]
16. CD56
Wang H; Zeng Y; Zhang M; Ma H; Xu B; Jiang H; Wang J; Li G
Hum Immunol; 2019 Oct; 80(10):871-877. PubMed ID: 31326139
[TBL] [Abstract][Full Text] [Related]
17. Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity.
Pievani A; Borleri G; Pende D; Moretta L; Rambaldi A; Golay J; Introna M
Blood; 2011 Sep; 118(12):3301-10. PubMed ID: 21821703
[TBL] [Abstract][Full Text] [Related]
18. CD56bright NK cells are enriched at inflammatory sites and can engage with monocytes in a reciprocal program of activation.
Dalbeth N; Gundle R; Davies RJ; Lee YC; McMichael AJ; Callan MF
J Immunol; 2004 Nov; 173(10):6418-26. PubMed ID: 15528382
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of human granzymes A, B, and K in natural killer cells and during CD8+ T cell differentiation in peripheral blood.
Bratke K; Kuepper M; Bade B; Virchow JC; Luttmann W
Eur J Immunol; 2005 Sep; 35(9):2608-16. PubMed ID: 16106370
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxicity of CD56(bright) NK cells towards autologous activated CD4+ T cells is mediated through NKG2D, LFA-1 and TRAIL and dampened via CD94/NKG2A.
Nielsen N; Ødum N; Ursø B; Lanier LL; Spee P
PLoS One; 2012; 7(2):e31959. PubMed ID: 22384114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
